Affinage

NKX6-1

Homeobox protein Nkx-6.1 · UniProt P78426

Length
367 aa
Mass
37.8 kDa
Annotated
2026-06-10
78 papers in source corpus 29 papers cited in narrative 29 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NKX6-1 is a homeodomain transcription factor that governs cell-fate specification and identity maintenance in both the endocrine pancreas and the ventral nervous system (PMID:11076772, PMID:10970877, PMID:23382704). Through its homeodomain it binds TAAT-containing DNA elements (consensus TTAATTAC), with an acidic C-terminal domain that lowers binding affinity while sharpening sequence selectivity for TAAT sites, and an amino-terminal repression domain (PMID:10799563, PMID:16101311). NKX6-1 is bifunctional: it represses targets such as the insulin and glucagon promoters—the latter by competing with Pax6 for the G1 element—and the alpha-cell determinant Arx, while activating its own promoter, HNF1alpha, and cell-cycle genes (PMID:10799563, PMID:17263687, PMID:23382704, PMID:15056733, PMID:20106981). In pancreatic development it acts downstream of Nkx2.2 and upstream of Ngn3 to drive beta-cell neogenesis during the secondary transition, and biochemically equivalent to Nkx6.2 such that distinct in vivo roles reflect divergent expression rather than intrinsic activity (PMID:11076772, PMID:17537793). In adult beta cells it maintains identity by repressing alternative (delta/alpha) cell programs, with its loss causing rapid-onset diabetes and acquisition of delta-cell characteristics (PMID:24035389, PMID:23382704). NKX6-1 drives postnatal beta-cell mass expansion through an Nr4a1/Nr4a3→E2F1/cyclin E pathway that promotes anaphase-promoting-complex–mediated p21 degradation and requires c-Fos and Aurora Kinase A (PMID:24706823, PMID:27164028, PMID:26030060), while also directly binding cyclin A2/B1 promoters and enhancing glucose-stimulated insulin secretion (PMID:18347054). In the CNS it specifies somatic motor neurons and V2 interneurons, controls motor-pool innervation specificity, and directs branchio-motoneuron migration by repressing guidance receptors Ret and Unc5h3 (PMID:10970877, PMID:18215620, PMID:14534138).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2000 High

    Established NKX6-1's position in the beta-cell differentiation hierarchy, answering whether it acts as a parallel or downstream effector of Nkx2.2.

    Evidence Double-mutant mouse epistasis (Nkx6.1 KO × Nkx2.2 KO) with histological analysis of pancreatic development

    PMID:11076772

    Open questions at the time
    • Direct transcriptional targets mediating the secondary-transition block were not defined
    • Did not establish whether the requirement was cell-autonomous within a specific progenitor stage
  2. 2000 High

    Demonstrated that NKX6-1 is essential for ventral neuronal fate specification, defining its CNS role parallel to its pancreatic one.

    Evidence Knockout mice with analysis of ventral neuronal fate markers in spinal cord

    PMID:10970877

    Open questions at the time
    • Direct downstream target genes controlling the fate switch were not identified
    • Did not address postmitotic versus progenitor-stage requirements
  3. 2000 High

    Defined the DNA-binding specificity and a bipartite regulatory architecture, establishing NKX6-1 as a repressor with an autonomous N-terminal repression domain and an affinity-modulating C-terminus.

    Evidence In vitro DNA-binding assays, Gal4 fusion reporters, mutagenesis in fibroblast and beta-cell lines; binding-site selection in a complementary study

    PMID:10567713 PMID:10799563

    Open questions at the time
    • The structural basis of C-terminal binding interference was not resolved
    • Endogenous repressed targets in vivo were not yet identified
  4. 2004 High

    Resolved how NKX6-1 can both repress and activate by demonstrating direct autoregulatory activation of its own beta-cell enhancer via the acidic C-terminal domain.

    Evidence Reporter assays, EMSA, ChIP, and mutagenesis in betaTC3 cells

    PMID:15056733

    Open questions at the time
    • Cofactors distinguishing activator from repressor mode were not identified
    • Generality of C-terminal activation across other targets unclear
  5. 2005 High

    Quantified how the C-terminal domain enhances TAAT sequence selectivity, clarifying the mechanistic role of this region in target discrimination.

    Evidence Quantitative gel shift, CD spectroscopy, and domain-swap fusions to the Pdx-1 homeodomain

    PMID:16101311

    Open questions at the time
    • Direct structural confirmation of DNA-induced conformational change absent
    • In vivo consequences of selectivity not tested
  6. 2007 High

    Defined NKX6-1's mechanism of glucagon repression and its functional requirement for insulin secretion, distinguishing competition from protein-protein inhibition.

    Evidence Gain/loss-of-function in INS-1 cell lines and primary rat islets, ChIP, EMSA, mutagenesis, co-IP, and GSIS assays

    PMID:15883383 PMID:17263687

    Open questions at the time
    • The weak Pax6 interaction's functional contribution was not quantified
    • Full set of co-repressed alpha-cell genes not mapped
  7. 2007 High

    Placed the earliest NKX6-1 requirement in Pdx1+ progenitors upstream of Ngn3 and showed its activity is interchangeable with Nkx6.2.

    Evidence Transgenic rescue with cell-type-specific promoter-driven Nkx6.1/Nkx6.2 in knockout mice

    PMID:17537793

    Open questions at the time
    • Molecular targets activating Ngn3 not identified
    • Why the two paralogs diverge spatiotemporally not explained at the regulatory level
  8. 2003 High

    Identified the mechanism of NKX6-1-controlled neuronal migration as repression of guidance receptors.

    Evidence Knockout mice, immunostaining for Ret and Unc5h3, axon tracing in hindbrain

    PMID:14534138

    Open questions at the time
    • Direct promoter binding to Ret/Unc5h3 loci not demonstrated
    • Whether repression is direct or indirect unresolved
  9. 2008 High

    Established NKX6-1 as a direct driver of beta-cell proliferation through cell-cycle gene activation, expanding its role beyond fate specification.

    Evidence Overexpression/RNAi in primary rat and human islets, microarray, ChIP at cyclin A2/B1 promoters, proliferation and GSIS assays; postmitotic motor-pool study in parallel

    PMID:18215620 PMID:18347054

    Open questions at the time
    • The full upstream cascade linking NKX6-1 to cyclin E was not yet defined
    • In vivo sufficiency for proliferation untested at this stage
  10. 2010 High

    Identified HNF1alpha as a direct activated target, broadening the NKX6-1 beta-cell transcriptional network.

    Evidence EMSA, ChIP, mutagenesis, and bidirectional gain/loss-of-function with reporter assays in beta cells

    PMID:20106981

    Open questions at the time
    • Functional consequences of HNF1alpha activation for beta-cell phenotype not dissected
    • Combinatorial cofactor requirements unknown
  11. 2011 Medium

    Tested whether elevated NKX6-1 alone suffices to expand beta-cell mass in vivo, returning a negative result that constrained the proliferation model.

    Evidence Inducible bigenic Cre transgenic overexpression with morphometry, BrdU, and glucose tolerance testing

    PMID:21964593

    Open questions at the time
    • Why in vivo overexpression fails where ex vivo islet overexpression succeeds was not resolved
    • Possible context- or age-dependent permissive factors not identified
  12. 2013 High

    Established NKX6-1 as both necessary and sufficient for beta-cell identity, defining direct repression of Arx and antagonism of Isl1 as the identity-maintenance mechanism.

    Evidence Conditional gain/loss-of-function mouse genetics, lineage tracing, ChIP at Arx promoter; adult conditional KO with genome-wide target analysis

    PMID:23382704 PMID:24035389

    Open questions at the time
    • Mechanism of the delta-cell drift in adult KO not fully traced to specific targets
    • Recruited corepressor complexes at Arx not identified
  13. 2014 High

    Delineated the bipartite Nr4a1/Nr4a3→E2F1/cyclin E→p21-degradation proliferation pathway and restricted NKX6-1's proliferative requirement to the postnatal window.

    Evidence Overexpression/knockdown in primary islets, Nr4a1 KO mice, BrdU assays; stage-specific conditional KO with beta-cell mass morphometry

    PMID:24706823 PMID:25277396

    Open questions at the time
    • How NKX6-1 selects postnatal versus prenatal proliferation programs unclear
    • Whether Nr4a induction is direct transcriptional binding not established
  14. 2015 Medium

    Added Aurora Kinase A as a direct target completing the proliferation circuit via p53 degradation, and revealed an oncogenic-context role through E-cadherin/EMT control.

    Evidence ChIP at AURKA promoter with islet proliferation assays; co-IP with BAF155/RBBP7 and EMT/invasion assays in cervical cancer cells

    PMID:26030060 PMID:26257059

    Open questions at the time
    • AURKA finding has limited independent replication
    • EMT cofactor recruitment shown by single Co-IP without reciprocal validation in primary tissue
  15. 2016 Medium

    Identified c-Fos as a required intermediary in the proliferation pathway and extended NKX6-1's direct targets to Notch1 (CNS) and IL-6 (cancer), illustrating context-dependent gene programs.

    Evidence c-Fos gain/loss in primary islets; CR2-enhancer reporter assays in neural progenitors; IL6 promoter pull-down and rescue in breast cancer cells

    PMID:27032575 PMID:27164028 PMID:27924849

    Open questions at the time
    • Notch1 and IL6 binding not confirmed by ChIP
    • Direct versus indirect c-Fos induction not resolved
  16. 2020 Medium

    Characterized upstream epigenetic control of NKX6-1 expression itself, linking signaling and lncRNA-mediated methylation to its levels in beta cells.

    Evidence INSM1-RACK1 co-IP with PI3K inhibition and acetyl-H4 ChIP at the Nkx6.1 promoter; lncRNA ROIT RNA pull-down, RIP, and bisulfite sequencing

    PMID:24407176 PMID:32008054

    Open questions at the time
    • These address regulation of NKX6-1, not its protein mechanism
    • Physiological generality of the ROIT-DNMT3a axis not established beyond obesity models
  17. 2024 Medium

    Revealed a sex-specific astrocyte function and identified Sema4A and Gabbr1 as targets, extending NKX6-1's CNS role beyond neuronal specification.

    Evidence Astrocyte-specific conditional KO with morphology, cholinergic synapse quantification, and epigenomic DNA-binding analysis, sex-stratified

    PMID:39731735

    Open questions at the time
    • Molecular basis of sex-dimorphic DNA-binding not mechanistically explained
    • Direct binding at Sema4A/Gabbr1 loci described but method not fully specified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How NKX6-1 switches between repressor and activator modes at individual loci, and which cofactor complexes dictate context-specific target selection across pancreas, neurons, astrocytes, and cancer, remains unresolved.
  • No unifying structural or cofactor model explains bifunctionality
  • Tissue-specific corepressor/coactivator recruitment incompletely mapped
  • Reconciliation of in vivo versus ex vivo proliferation outcomes unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 8 GO:0140110 transcription regulator activity 6
Localization
GO:0005634 nucleus 5
Pathway
R-HSA-1266738 Developmental Biology 6 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1640170 Cell Cycle 3
Partners
BAF155ISL1PAX6RBBP7

Evidence

Reading pass · 29 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 Genetic epistasis in mice places Nkx6.1 downstream of Nkx2.2 in the major pathway of beta-cell differentiation: Nkx6.1/Nkx2.2 double-mutant islet development is identical to the Nkx2.2 single mutant, and Nkx6.1 single knockout specifically blocks beta-cell neogenesis during the secondary transition (E13 onward) while leaving primary-transition islets intact. Double-mutant mouse genetics (Nkx6.1 KO × Nkx2.2 KO epistasis), histological analysis of pancreatic development Development High 11076772
2000 Nkx6.1 is required for somatic motor neuron and V2 interneuron fate specification in the ventral spinal cord; its loss causes a dorsal-to-ventral switch in progenitor identity and complete block of motor neuron and V2 interneuron generation with compensatory ventral expansion of V1 neurons. Targeted mutation/knockout mice, analysis of ventral neuronal fate markers Genes & Development High 10970877
2000 Nkx6.1 homeodomain binds the DNA consensus sequence TTAATTAC (single copy); full-length Nkx6.1 has reduced DNA-binding affinity due to an acidic C-terminal domain that acts as a mobile binding-interference domain. Nkx6.1 represses transcription through isolated Nkx6.1 binding sites in fibroblasts and represses the insulin promoter through TAAT-containing sequences in beta-cell lines; the repression domain maps to the amino terminus. In vitro DNA-binding assays, Gal4 one-hybrid fusion reporter assays, site-directed mutagenesis, transfection in fibroblast and beta-cell lines Journal of Biological Chemistry High 10799563
2000 Beta-cell-specific expression of Nkx6.1 is regulated at both transcriptional and translational levels: sequences from −5.6 to +1.0 kb drive beta-cell-specific promoter activity dependent on an ~−800 bp element; PDX1 and Nkx2.2 bind this element by EMSA; the long 5′-UTR functions as a potent internal ribosomal entry site (IRES) providing cell-type-specific translational regulation. Promoter-reporter assays, EMSA (electrophoretic mobility shift assay), dicistronic IRES assay, gene structure mapping Journal of Biological Chemistry High 10938085
1999 The Nkx6.1 homeodomain binds DNA at the sequence TTAATTG/A (identified by in vitro binding site selection); full-length Nkx6.1 fails to activate a reporter containing this site despite robust in vitro binding, consistent with a repressor or context-dependent function; stable expression of Nkx6.1 in alpha-cell-like MSL-G-AN cells induces endogenous insulin gene expression in a subset of cells. In vitro binding site selection, reporter assays, stable transfection in alpha-cell lines FEBS Letters Medium 10567713
2004 Nkx6.1 is a bifunctional transcription factor: it acts as a transcriptional activator at a beta-cell-specific enhancer element (−157 to −30 bp) in its own promoter through direct binding to an A/T-rich sequence, mediated by an acidic sequence in the C-terminal domain; this autoregulatory activation is demonstrated by EMSA (in vitro binding) and chromatin immunoprecipitation (in vivo occupancy in betaTC3 cells). Reporter gene assays, EMSA, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, dicistronic controls Molecular Endocrinology High 15056733
2005 The C-terminal domain of Nkx6.1 enhances sequence selectivity of the homeodomain for TAAT DNA sequences ~10-fold (while reducing affinity ~2-fold); this selectivity is functionally preserved in mammalian cells; the effect maps to residues 318–338, which impart minimal secondary structure change to unbound protein, suggesting conformational adjustments upon DNA binding mediate selectivity; the C terminus can confer these properties in a modular fashion when fused to the Pdx-1 homeodomain. Quantitative gel shift analysis, reporter gene assays, deletion/mutational analysis, circular dichroism spectroscopy, domain-swap (heterologous homeodomain fusion) Biochemistry High 16101311
2005 Nkx6.1 suppresses glucagon gene expression in islet beta-cell lines: overexpression in glucagon-expressing class 1 INS-1 cells suppresses glucagon without affecting other beta-cell transcription factors; RNAi knockdown in glucose-responsive class 3 cells doubles glucagon mRNA independently of Pdx1 effects; RNAi knockdown in class 3 cells and primary rat islets reduces glucose-stimulated insulin secretion (GSIS) from ~14-fold to ~4-fold stimulation. Adenoviral overexpression, RNAi knockdown in INS-1-derived cell lines and primary rat islets, GSIS assays, qRT-PCR PNAS High 15883383
2007 Nkx6.1 inhibits glucagon gene transcription by competing with Pax6 for binding to the G1 element of the glucagon promoter; mutagenesis identifies the Pax6-binding site within G1 as the preferential Nkx6.1 interaction site; ChIP confirms Nkx6.1 occupancy at the glucagon promoter in vivo; weak physical interaction between Pax6 and Nkx6.1 is detected both in vitro and in vivo, suggesting predominantly competitive rather than protein–protein inhibition. Transient transfection reporter assays, gel-shift assays (EMSA), site-directed mutagenesis of G1 element, chromatin immunoprecipitation (ChIP), co-immunoprecipitation (in vitro and in vivo) Biochemical Journal High 17263687
2007 Nkx6.1 and Nkx6.2 possess equivalent biochemical activities for beta-cell specification when expressed in Pdx1+ multipotent pancreatic progenitors; their distinct in vivo roles arise from divergent spatiotemporal expression, not from intrinsic biochemical differences. Rescue of beta-cell formation in Nkx6.1 mutant mice requires expression in Pdx1+ progenitors but not in Ngn3+ committed endocrine progenitors, placing a first Nkx6.1 requirement upstream of Ngn3 activation. Transgenic rescue experiments in Nkx6.1 knockout mice using Pdx1-promoter-driven Nkx6.1 and Nkx6.2 transgenes; lineage-specific expression via Ngn3-promoter transgenes Development High 17537793
2008 Nkx6.1 overexpression in rat primary islets stimulates beta-cell proliferation by upregulating a cadre of cell cycle genes (cyclins A, B, E and regulatory kinases); Nkx6.1 directly binds the cyclin A2 and B1 gene promoters as shown by ChIP; cyclin E upregulation precedes other cyclins and is sufficient to activate islet cell proliferation; Nkx6.1 overexpression also enhances GSIS while maintaining beta-cell identity; overexpression in human islets increases thymidine incorporation while retaining GSIS. Adenoviral overexpression and RNAi knockdown in primary rat and human islets, BrdU/thymidine incorporation, microarray, qRT-PCR, immunoblot, chromatin immunoprecipitation (ChIP), immunocytochemistry Molecular and Cellular Biology High 18347054
2008 Nkx6.1 (and Nkx6.2) expression in certain motor neuron pools soon after cell cycle exit controls muscle nerve formation and innervation specificity of individual muscles, demonstrating that postmitotic transcriptional identity established by Nkx6.1 regulates target muscle specificity. Mouse genetics (Nkx6.1 conditional and conventional knockouts), retrograde labeling, analysis of motor pool identity markers and nerve trajectories Neuron High 18215620
2003 Nkx6.1 is required for migration and axon pathfinding of cranial branchio-motoneurons in the hindbrain in a cell-autonomous manner; loss of Nkx6.1 causes ectopic expression of cell-surface receptors Ret and Unc5h3 in premigratory facial branchio-motoneurons without altering the rhombomeric environment, indicating Nkx6.1 controls migration by regulating guidance receptor expression. Nkx6.1 knockout mouse analysis, immunostaining for Ret and Unc5h3, axon tracing, analysis of rhombomeric environment Development High 14534138
2009 In the ventral midbrain, Nkx6-1 acts as a fate determinant of Brn3a+ red nucleus neurons; its loss partially dorsalizes progenitors with a subset adopting an alternative fate marked by ectopic Dbx1 and Otx2 expression; in postmitotic Isl1+ oculomotor and trochlear neurons, Nkx6-1 controls migration and axon outgrowth by regulating at least three axon guidance/neuronal migration molecules. Nkx6-1 knockout mouse analysis, in situ hybridization, immunostaining for fate markers, analysis of axon trajectories Development Medium 19592574
2013 Nkx6.1 is both necessary and sufficient for insulin-producing beta-cell specification: heritable Nkx6.1 expression in endocrine precursors respecifies non-beta endocrine precursors to beta-cell lineage; conditional inactivation in endocrine precursors or beta cells converts them to alternative endocrine lineages. Nkx6.1 directly binds and represses the alpha-cell determinant Arx promoter (shown by ChIP), and Nkx6.1 and the Arx activator Isl1 antagonistically regulate Arx transcription. Conditional gain- and loss-of-function mouse genetics, lineage tracing, chromatin immunoprecipitation (ChIP) for Arx promoter, gene expression analysis PLoS Genetics High 23382704
2013 Conditional inactivation of Nkx6.1 in adult beta cells causes rapid-onset diabetes and hypoinsulinemia; genome-wide analysis (ChIP-seq implied) reveals an Nkx6.1-controlled gene regulatory network essential for insulin biosynthesis, secretion, and beta-cell proliferation. Over time, Nkx6.1-deficient beta cells acquire molecular characteristics of delta cells, establishing a molecular link between impaired Nkx6.1 function and loss of beta-cell identity. Conditional knockout in adult mice, genome-wide gene regulation analysis, functional insulin secretion and proliferation assays, immunostaining for delta-cell markers Cell Reports High 24035389
2014 Nkx6.1 drives beta-cell proliferation through a bipartite pathway: Nkx6.1 induces expression of orphan nuclear receptors Nr4a1 and Nr4a3, which are both necessary and sufficient for Nkx6.1-mediated beta-cell proliferation. Downstream, Nkx6.1 and Nr4a receptors increase E2F1 and cyclin E1 expression, and induce components of the anaphase-promoting complex (including UBE2C) leading to degradation of the cell-cycle inhibitor p21. Adenoviral overexpression of Nkx6.1 and Nr4a receptors in primary rat islets, shRNA knockdown, global Nr4a1 knockout mice, BrdU proliferation assays, immunoblot for cell cycle proteins PNAS High 24706823
2014 Nkx6.1 is required specifically for postnatal (not prenatal) beta-cell mass expansion; conditional inactivation of Nkx6.1 in newly formed beta cells causes a drastic decrease in early postnatal beta-cell proliferation, reduced beta-cell mass, and glucose intolerance. Nkx6.1 regulates expression of beta-cell maturation markers and nutrient sensors Glut2 and Glp1r, suggesting it enables beta cells to respond to nutrient-dependent proliferation signals after birth. Conditional knockout mouse genetics (beta-cell-specific inactivation at distinct developmental stages), BrdU incorporation, beta-cell mass morphometry, glucose tolerance tests Diabetes High 25277396
2015 NKX6.1 functions as a metastasis suppressor by inhibiting epithelial-to-mesenchymal transition (EMT): NKX6.1 directly enhances E-cadherin mRNA expression by recruiting the BAF155 coactivator, and represses vimentin and N-cadherin by recruiting the RBBP7 corepressor, demonstrating that NKX6.1 acts through distinct epigenetic modifiers depending on target gene context. NKX6.1 overexpression/knockdown in cervical cancer cells and in vivo xenograft, co-immunoprecipitation with BAF155 and RBBP7, luciferase reporter assays, invasion assays, clinical tumor analysis Oncogene Medium 26257059
2015 Aurora Kinase A (AURKA) is a direct transcriptional target of Nkx6.1 (ChIP shows Nkx6.1 localizes to the AURKA promoter); AURKA is necessary for Nkx6.1-mediated beta-cell proliferation (shown by shRNA knockdown and pharmacological inhibition); AURKA overexpression is sufficient to induce beta-cell proliferation; mechanistically, AURKA phosphorylates p53, targeting it for degradation and permitting cell cycle progression. Chromatin immunoprecipitation (ChIP) at AURKA promoter, adenoviral overexpression of AURKA in primary rat islets, shRNA knockdown, pharmacological AURKA inhibition, BrdU incorporation, histone H3 phosphorylation assay, immunoblot for p53 phosphorylation Islets Medium 26030060
2016 Nkx6.1-mediated upregulation of Nr4a1, Nr4a3, and VGF (a peptide hormone) is dependent on c-Fos expression; c-Fos overexpression activates Nkx6.1-responsive genes and increases beta-cell proliferation, insulin secretion, and cellular survival; c-Fos knockdown impedes Nkx6.1-mediated beta-cell proliferation and insulin secretion, placing c-Fos as a required intermediary in the Nkx6.1 pathway. Adenoviral overexpression and shRNA knockdown of c-Fos in primary rat islets, measurement of Nkx6.1 target gene expression, BrdU proliferation assay, GSIS assay FEBS Letters Medium 27164028
2010 NKX6.1 directly binds a cis-regulatory element in the HNF1alpha promoter (demonstrated by EMSA and ChIP) and is a major activator of HNF1alpha in beta cells; site-directed mutagenesis of the NKX6.1 core-binding sequence eliminates NKX6.1-mediated activation and substantially decreases HNF1alpha promoter activity; overexpression or siRNA knockdown of Nkx6.1 correspondingly increases or decreases HNF1alpha expression. EMSA, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, adenoviral overexpression, siRNA knockdown, reporter assays in beta cells Journal of Biological Chemistry High 20106981
2016 Nkx6.1 directly interacts with the CR2 cis-element (a conserved 139-bp enhancer in the second intron of the Notch1 locus) in ventral neural stem/progenitor cells of the developing spinal cord, and regulates Notch1 expression; Nkx6.1 knockdown or overexpression correspondingly down- or upregulates Notch1 in NSPCs. Luciferase reporter assays with CR2 element, Nkx6.1 knockdown/overexpression in neural progenitor cells, CR2-GFP transgenic mouse, immunostaining Scientific Reports Medium 27924849
2016 NKX6.1 directly upregulates IL-6 (IL6) gene expression in basal-like breast cancer cells by binding to the proximal region of the IL6 promoter (shown by pull-down assay); NKX6.1 depletion reduces IL6 promoter activity and expression; restoring IL-6 rescues the reduced cell growth of NKX6.1-depleted cells, establishing a NKX6.1→IL-6→cell growth axis. Reporter assay (IL6 promoter), DNA pull-down assay, siRNA knockdown, forced IL-6 expression rescue experiment, orthotopic xenograft Experimental Cell Research Medium 27032575
2014 Activation of NKX6.1 expression in AR42J cells (trans-differentiation model) is mediated through the insulin receptor (InR)/PI3K/AKT signaling pathway downstream of INSM1-RACK1 interaction; acetyl-H4 modification is elevated on the Nkx6.1 gene promoter/enhancer upon INSM1 induction, and PI3K inhibition (LY294002) blocks Nkx6.1 expression, linking chromatin acetylation at the Nkx6.1 locus to upstream InR signaling. Co-immunoprecipitation (INSM1-RACK1), AKT phosphorylation immunoblot, PI3K inhibitor treatment, chromatin immunoprecipitation for acetyl-H4 at Nkx6.1 promoter, RT-PCR for Nkx6.1 and insulin Cellular Signalling Medium 24407176
2020 The lncRNA ROIT promotes Nkx6.1 expression by binding to DNA methyltransferase 3a (DNMT3a) and causing its degradation through the ubiquitin-proteasome pathway, thereby reducing methylation of the Nkx6.1 promoter; this establishes an obesity-responsive epigenetic mechanism controlling Nkx6.1 expression in beta cells. RNA pull-down, RNA immunoprecipitation, co-immunoprecipitation, bisulfite sequencing of Nkx6.1 promoter, ROIT overexpression/knockdown in MIN6 cells and primary islets, siRNA in vivo Diabetologia Medium 32008054
2024 In ventral spinal cord astrocytes, Nkx6.1 exhibits sex-specific DNA-binding properties and epigenomic remodeling; deletion of Nkx6.1 in astrocytes produces sex-dimorphic effects on astrocyte morphology and cholinergic synapse formation; Semaphorin 4A (Sema4A) and Gabbr1 are identified as direct Nkx6.1 targets regulating astrocyte morphology. Astrocyte-specific Nkx6.1 conditional knockout mice, analysis of astrocyte morphology, motor function assessment, cholinergic synapse quantification, genomic/epigenomic analysis of DNA-binding (ATAC-seq or ChIP implied), sex-stratified analysis Cell Reports Medium 39731735
1997 Human NKX6A (NKX6-1) encodes a 367-amino acid homeodomain protein with 97% identity to hamster Nkx6.1; the NK decapeptide and homeodomain are identical between human and hamster; the gene has three exons spanning ~4.8 kb and maps to chromosome 4q21.2-q22. cDNA cloning, genomic structure characterization, fluorescence in situ hybridization (FISH), YAC mapping Genomics Medium 9119408
2011 Transgenic overexpression of Nkx6.1 in beta cells in vivo (using inducible bigenic Cre-based system) does not increase beta-cell proliferation, beta-cell mass, or improve glucose metabolism in normal or beta-cell-depleted mice, demonstrating that elevated Nkx6.1 levels in mature beta cells in vivo are insufficient to stimulate beta-cell expansion. Bigenic inducible Cre-recombinase transgenic mouse model, BrdU incorporation, morphometric beta-cell mass analysis, glucose tolerance testing, partial beta-cell ablation model Molecular Endocrinology Medium 21964593

Source papers

Stage 0 corpus · 78 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. Development (Cambridge, England) 427 11076772
2013 Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells. Cell reports 275 24035389
2015 Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem cell reports 235 25843049
2000 Ventral neural patterning by Nkx homeobox genes: Nkx6.1 controls somatic motor neuron and ventral interneuron fates. Genes & development 224 10970877
2013 Enrichment of human embryonic stem cell-derived NKX6.1-expressing pancreatic progenitor cells accelerates the maturation of insulin-secreting cells in vivo. Stem cells (Dayton, Ohio) 214 23897760
2013 Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. PLoS genetics 180 23382704
2005 The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proceedings of the National Academy of Sciences of the United States of America 134 15883383
2020 NKX6.1 transcription factor: a crucial regulator of pancreatic β cell development, identity, and proliferation. Stem cell research & therapy 104 33121533
2007 The transcription factors Nkx6.1 and Nkx6.2 possess equivalent activities in promoting beta-cell fate specification in Pdx1+ pancreatic progenitor cells. Development (Cambridge, England) 97 17537793
2008 Stimulation of human and rat islet beta-cell proliferation with retention of function by the homeodomain transcription factor Nkx6.1. Molecular and cellular biology 91 18347054
2014 Nkx6.1 regulates islet β-cell proliferation via Nr4a1 and Nr4a3 nuclear receptors. Proceedings of the National Academy of Sciences of the United States of America 85 24706823
2008 Early motor neuron pool identity and muscle nerve trajectory defined by postmitotic restrictions in Nkx6.1 activity. Neuron 80 18215620
2018 Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1. Stem cell research & therapy 68 29361979
2009 Nkx6-1 controls the identity and fate of red nucleus and oculomotor neurons in the mouse midbrain. Development (Cambridge, England) 67 19592574
2003 Molecular mapping of the origin of postnatal spinal cord ependymal cells: evidence that adult ependymal cells are derived from Nkx6.1+ ventral neural progenitor cells. The Journal of comparative neurology 67 12528188
2007 Peroxisome proliferator-activated receptor-gamma regulates expression of PDX-1 and NKX6.1 in INS-1 cells. Diabetes 61 17192469
2003 Nkx6.1 controls migration and axon pathfinding of cranial branchio-motoneurons. Development (Cambridge, England) 58 14534138
2000 Transcriptional and translational regulation of beta-cell differentiation factor Nkx6.1. The Journal of biological chemistry 56 10938085
2000 Beta-cell differentiation factor Nkx6.1 contains distinct DNA binding interference and transcriptional repression domains. The Journal of biological chemistry 53 10799563
2014 High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 52 24407576
2008 Generation and characterization of Ptf1a antiserum and localization of Ptf1a in relation to Nkx6.1 and Pdx1 during the earliest stages of mouse pancreas development. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 51 18347078
2015 Progenitor potential of nkx6.1-expressing cells throughout zebrafish life and during beta cell regeneration. BMC biology 46 26329351
2002 Caenorhabditis elegans cog-1 locus encodes GTX/Nkx6.1 homeodomain proteins and regulates multiple aspects of reproductive system development. Developmental biology 46 12482710
2004 The transcriptional repressor Nkx6.1 also functions as a deoxyribonucleic acid context-dependent transcriptional activator during pancreatic beta-cell differentiation: evidence for feedback activation of the nkx6.1 gene by Nkx6.1. Molecular endocrinology (Baltimore, Md.) 45 15056733
2010 NKX6.1 promotes PDX-1-induced liver to pancreatic β-cells reprogramming. Cellular reprogramming 41 21108535
2016 Directed differentiation of human iPSC into insulin producing cells is improved by induced expression of PDX1 and NKX6.1 factors in IPC progenitors. Journal of translational medicine 38 27998294
2020 Controlled clustering enhances PDX1 and NKX6.1 expression in pancreatic endoderm cells derived from pluripotent stem cells. Scientific reports 36 31988329
2020 Obesity-induced reduced expression of the lncRNA ROIT impairs insulin transcription by downregulation of Nkx6.1 methylation. Diabetologia 36 32008054
2015 NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene 34 26257059
2010 Nkx6.1 and nkx6.2 regulate alpha- and beta-cell formation in zebrafish by acting on pancreatic endocrine progenitor cells. Developmental biology 34 20122912
1999 Cloning and DNA-binding properties of the rat pancreatic beta-cell-specific factor Nkx6.1. FEBS letters 33 10567713
2014 Postnatal β-cell proliferation and mass expansion is dependent on the transcription factor Nkx6.1. Diabetes 32 25277396
2016 Nkx6.1-mediated insulin secretion and β-cell proliferation is dependent on upregulation of c-Fos. FEBS letters 30 27164028
2007 The beta-cell specific transcription factor Nkx6.1 inhibits glucagon gene transcription by interfering with Pax6. The Biochemical journal 29 17263687
2018 Differentiation of human pluripotent stem cells into two distinct NKX6.1 populations of pancreatic progenitors. Stem cell research & therapy 27 29615106
2015 Aurora Kinase A is critical for the Nkx6.1 mediated β-cell proliferation pathway. Islets 23 26030060
2014 Silymarin induces expression of pancreatic Nkx6.1 transcription factor and β-cells neogenesis in a pancreatectomy model. Molecules (Basel, Switzerland) 23 24739928
2011 Transgenic overexpression of the transcription factor Nkx6.1 in β-cells of mice does not increase β-cell proliferation, β-cell mass, or improve glucose clearance. Molecular endocrinology (Baltimore, Md.) 23 21964593
2020 PDX1- /NKX6.1+ progenitors derived from human pluripotent stem cells as a novel source of insulin-secreting cells. Diabetes/metabolism research and reviews 21 32857429
2010 Dynamic expression patterns of Nkx6.1 and Nkx6.2 in the developing mes-diencephalic basal plate. Developmental dynamics : an official publication of the American Association of Anatomists 21 20549744
2006 Generation and characterization of monoclonal antibodies against the transcription factor Nkx6.1. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 21 16401696
2018 NKX6.1 induced pluripotent stem cell reporter lines for isolation and analysis of functionally relevant neuronal and pancreas populations. Stem cell research 20 29734117
2016 Transcriptional Regulation of Notch1 Expression by Nkx6.1 in Neural Stem/Progenitor Cells during Ventral Spinal Cord Development. Scientific reports 20 27924849
2001 Chicken Nkx6.1 expression at advanced stages of development identifies distinct brain nuclei derived from the basal plate. Mechanisms of development 20 11287211
2020 NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer. International journal of molecular sciences 19 32707737
2014 Extra-nuclear activity of INSM1 transcription factor enhances insulin receptor signaling pathway and Nkx6.1 expression through RACK1 interaction. Cellular signalling 18 24407176
2010 Nkx6 genes pattern the frog neural plate and Nkx6.1 is necessary for motoneuron axon projection. Developmental biology 17 21035438
2014 Control of astrocyte progenitor specification, migration and maturation by Nkx6.1 homeodomain transcription factor. PloS one 16 25285789
2005 The C-terminal domain of the beta cell homeodomain factor Nkx6.1 enhances sequence-selective DNA binding at the insulin promoter. Biochemistry 16 16101311
2019 High-throughput transcriptome analysis reveals that the loss of Pten activates a novel NKX6-1/RASGRP1 regulatory module to rescue microphthalmia caused by Fgfr2-deficient lenses. Human genetics 15 31691004
1997 Isolation, characterization, and chromosomal mapping of the human Nkx6.1 gene (NKX6A), a new pancreatic islet homeobox gene. Genomics 15 9119408
2018 NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy. Genes, chromosomes & cancer 14 29363224
2021 Nkx6.1 enhances neural stem cell activation and attenuates glial scar formation and neuroinflammation in the adult injured spinal cord. Experimental neurology 13 34343529
2018 Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas. Diagnostic cytopathology 13 30284410
2017 Nkx6.1 decline accompanies mitochondrial DNA reduction but subtle nucleoid size decrease in pancreatic islet β-cells of diabetic Goto Kakizaki rats. Scientific reports 13 29142323
2021 NKX6-1 mediates cancer stem-like properties and regulates sonic hedgehog signaling in leiomyosarcoma. Journal of biomedical science 12 33906647
2019 Zebrafish prdm12b acts independently of nkx6.1 repression to promote eng1b expression in the neural tube p1 domain. Neural development 11 30813944
2013 Reprogramming of enteroendocrine K cells to pancreatic β-cells through the combined expression of Nkx6.1 and Neurogenin3, and reaggregation in suspension culture. Biochemical and biophysical research communications 10 24365150
2010 Distinct regulation of hepatic nuclear factor 1alpha by NKX6.1 in pancreatic beta cells. The Journal of biological chemistry 10 20106981
2021 Increased NKX6.1 expression and decreased ARX expression in alpha cells accompany reduced beta-cell volume in human subjects. Scientific reports 8 34493754
2018 Methylation in the promoter regions of WT1, NKX6-1 and DBC1 genes in cervical cancer tissues of Uygur women in Xinjiang. Genetics and molecular biology 8 29658966
2011 Isolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord. BMC neuroscience 8 21985235
2024 Deletion of RFX6 impairs iPSC-derived islet organoid development and survival, with no impact on PDX1+/NKX6.1+ progenitors. Diabetologia 7 39080045
2017 Efficient Differentiation of Pluripotent Stem Cells to NKX6-1+ Pancreatic Progenitors. Journal of visualized experiments : JoVE 7 28362406
2016 A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. Experimental cell research 7 27032575
2023 Deficiency of transcription factor Nkx6.1 does not prevent insulin secretion in INS-1E cells. Scientific reports 6 36639413
2020 MiR-190b impedes pancreatic β cell proliferation and insulin secretion by targeting NKX6-1 and may associate to gestational diabetes mellitus. Journal of receptor and signal transduction research 6 32862769
2020 Netrin-1/DCC Signaling Differentially Regulates the Migration of Pax7, Nkx6.1, Irx2, Otp, and Otx2 Cell Populations in the Developing Interpeduncular Nucleus. Frontiers in cell and developmental biology 6 33195252
2013 Xenopus Nkx6.1 and Nkx6.2 are required for mid-hindbrain boundary development. Development genes and evolution 6 23423436
2008 Specificity of four monoclonal anti-NKx6-1 antibodies. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 6 18212389
2022 Highly Efficient Differentiation of Human Pluripotent Stem Cells into Pancreatic Progenitors Co-expressing PDX1 and NKX6.1. Methods in molecular biology (Clifton, N.J.) 5 33190184
2021 Increased frequency of β cells with abnormal NKX6.1 expression in type 2 diabetes but not in subjects with higher risk for type 2 diabetes. BMC endocrine disorders 4 33711989
2024 Sex-specific astrocyte regulation of spinal motor circuits by Nkx6.1. Cell reports 3 39731735
2024 MIR124-3 and NKX6-1 hypermethylation profiles accurately predict metachronous gastric lesions in a Caucasian population. Clinical epigenetics 2 39169394
2022 NKX6-1 Is a Less Sensitive But Specific Biomarker of Chromophobe Renal Cell Carcinoma. The American journal of surgical pathology 2 35256556
2022 Micro-RNA-124-5p promotes insulin producing cell differentiation through regulating transcriptional factor NKX6.1. Biochemistry and biophysics reports 1 35592615
2021 Generation of a Novel Nkx6-1 Venus Fusion Reporter Mouse Line. International journal of molecular sciences 1 33810480
2026 NKX6.1 mRNA copy number is an actionable biomarker associated with islet function and clinical outcomes after islet transplantation. Science translational medicine 0 41880516

Missed literature

Know a paper Affinage missed for NKX6-1? Flag it for the maintainers and the community.

No submissions yet.